Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India ・Tirzepatide is used to manage type 2 ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Per the agreement, the Indianapolis-based drugmaker will continue to manufacture the drug, which India-based Cipla will sell under a new brand name.

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Indian pharma giant Cipla on Thursday announced an agreement with US pharmaceutical firm Eli Lilly, acquiring the rights to ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...